Sanofi, Re­gen­eron say Dupix­ent suc­ceeds in an­oth­er late-stage COPD study, set­ting up fil­ing for FDA ap­proval

The megablock­buster an­ti-in­flam­ma­to­ry drug Dupix­ent suc­ceed­ed in a sec­ond late-stage COPD tri­al, Sanofi and Re­gen­eron said Mon­day, as the two drug­mak­ers plan to file for ap­proval by year’s end.

The com­mon lung dis­ease would be a ma­jor new mar­ket for Dupix­ent, a bi­o­log­ic first ap­proved in 2017 that has grown in­to one of the in­dus­try’s best-sell­ing drugs by treat­ing a range of in­flam­ma­to­ry con­di­tions such as atopic der­mati­tis and asth­ma. The topline re­sults from the NO­TUS tri­al fol­low pre­vi­ous suc­cess of the Phase III BORE­AS study an­nounced in March.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER